Estrogen replacement therapy in breast cancer survivors: A matched-controlled series

Menopause

Volumn 10, Issue 4, 2003, Pages 277-285

  Decker, David A ^a,b   Pettinga, Jane E ^a   VanderVelde, Nancy ^a   Huang, Raywin R ^a   Kestin, Larry ^a   Burdakin, John H ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Breast cancer; Estrogen deficiency symptoms; Estrogen replacement therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE; PROGESTERONE; TAMOXIFEN; VINCRISTINE;

AGE; ANXIETY DISORDER; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DYSPAREUNIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MOOD DISORDER; MORTALITY; RISK FACTOR; SYMPTOMATOLOGY;

EID: 0038786585     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000061806.76067.E9     Document Type: Article

References (39)

1. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737-2744.
2. Vassilopoulou-Sellin R, Zolinski C. Estrogen replacement therapy in women with breast cancer: a survey of patient attitudes. Am J Med Sci 1992;117:1038-1041.
3. Barton D, Loprinzi CL, Veeder M, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Proc Am Clin Oncol 1997;16:46a.
4. Bergmans MG, Merkus JM, Corber RS, Schellekens LA, Ubachs JMH. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987;9:227-234.
5. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158.
6. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-973.
7. Loprinzi CL, Kugler JW, Sloan J, et al. Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000;356:2059-2063.
8. Taylor CW, Green S, Dalton WS, et al. Multicenter randomized trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998;16:994-999.
9. Welch CW. Host factors affecting the growth in carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 1985;45:3415-3443.
10. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
11. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
12. Castration and Oestrogen Therapy. In: Stoll BA, ed. Endocrine Therapy in Malignant Disease. Philadelphia, PA: W.B. Saunders, 1972:156-158.
13. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997;65:89-93.
14. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-375.
15. Stoll BA. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 1989;25:1909-1913.
16. Powles TJ, Hickish T, Casey S, O'Brien M. Hormone replacement after breast cancer. Lancet 1993;342:60-61.
17. Eden JA, Bush T, Nand S, Wren BG. A case-controlled study of combined continuous hormone replacement therapy amongst women with a personal history of breast cancer. Menopause 1995; 2:67-72.
18. Ursic-Vrscaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146-151.
19. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482-1487.
20. DeSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol 2000;23:541-545.
21. Marsden J, Whitehead M, A'Hern R, Baum M, Sacks N. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 2000;37:292-299.
22. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-762.
23. Peters GN, Fodera T, Sabol J, Jones S, Euthus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up. Ann Surg Oncol 2001;8:828-832.
24. Beckmann MW, Mohrmann T, Kuschel B, et al. Hormonerstaztherapie (HRT) nach mammakarzinomerkrankung - ergebnisse einer beobachtungs - studie. Geburtshilfe Frauenheilkd 1998;58: 193-196.
25. Puthugramam K, Natrajan MD, Gambrell D. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002;187:289-295.
26. Decker DA, Pettinga JE, Cox TC, Burdakin JH, Jaiyesimi IA, Benitez PR. Hormone replacement therapy (HRT) in breast cancer survivors. Breast J 1997;3:63-68.
27. Decker DA, Pettinga JE, Kestin L, et al. Estrogen replacement therapy (ERT) in breast cancer survivors [Abstract]. In: ASCO Proceedings 2000;19:598a.
28. Coope J, Thomson JM, Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975;4:139-143.
29. Stadberg E, Mattsson L-A, Milsom I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet Gynecol Scand 1997;76:442-448.
30. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancer after hormone replacement therapy. Breast Cancer Res Treat 1996;38:325-334.
31. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999;91:264-270.
32. Lipman ME, Bolan G. Estrogen-responsive human breast cancer in long term tissue culture. Nature 1975;256:592-593.
33. Carter AC, Sedransk N, Kelley RM, et al. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients-report of the Cooperative Breast Cancer Group. JAMA 1977;327: 2079-2085.
34. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981;304:16-21.
35. Ribeiro GG. A clinical trial to compare the use of tamoxifen vs stilboestrol in the treatment of post-menopausal women with advanced breast cancer. In: Review on Endocrine Related Cancer, suppl 9. Wilmington, DE: Stuart Pharmaceuticals; 1980:409-414.
36. Petthambaram PP, Ingle JN, Suman VJ, et al. Randomized trial of diethylstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999;54:117-122.
37. Palshoft T, Carstensen B, Mouridsen HT, Dombernowsky P. Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. In: Review on Endocrine Related Cancer. Wilmington, DE: Stuart Pharmaceuticals; 1985;17s:43-50.
38. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst 2001;93:1714-1723.
39. Yao K, Lee E-S, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-2036.